ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1258

Polycystic Kidney Disease and Race

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Hayward, Alexandra, University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • McGill, Rita L., University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Saunders, Milda Renne, University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Chapman, Arlene B., University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
Background

Racial/ethnic differences in the development of kidney failure (ESKD) and transplant (TX) access are well-documented. ESKD is anticipated in familial autosomal dominant polycystic kidney disease (ADPKD), providing the opportunity for greater ESKD preparation. We sought to define the impact of race on ESKD/TX outcomes in ADPKD.

Methods

White (W), African-American (A), or Hispanic (H) ADPKD patients were identified in USRDS 1/2000-6/2018; demographic and laboratory data were obtained. Median income was derived from US Census. Models included: age at ESKD (linear), pre-emptive TX (logistic), and TX after dialysis initiation (Cox), adjusted for age, sex, albumin, hemoglobin, eGFR, insurance, income, ESKD Network, and employment, with W as referent.

Results

Among 41,485 patients, (77.3% W, 13.3% A, 9.4% H), characteristics/outcomes are shown in Table 1. AA and H had lower median income and less private insurance, pre-ESKD nephrology care, and employment. For AA and H, peritoneal dialysis and TX were less common than in W. Albumin, hemoglobin, and GFR were lowest in A.
ESKD occurred 2.2 ± 0.2 and 4.8 ± 0.3 years earlier in A and H, compared to W. Adjusted odds of pre-emptive TX were 0.38(0.33, 0.42) and 0.47(0.40, 0.55) for A and H. Adjusted hazards for TX after dialysis initiation were 0.60(0.55, 0.65) for A and 0.78(0.72, 0.85, for H, P<0.001 for all. TX rates for A vs W by network are shown in Figure 1.

Conclusion

Despite the hereditary nature of ADPKD, renal outcomes differ by race, attributed to in part, economic and geographic factors. Health inequity is a contributing factor to patient outcomes in ADPKD that needs to be addressed.